Viatris Launches Inpefa In UAE, Supporting Viatris' Strategy To Expand Access To Treatment In Key Markets Outside Of U.S. And Europe
Benzinga Newsdesk 9 months ago
News
Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular DiseasesPITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the launch of
Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases
PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment. Future launches are planned in multiple countries over the next several years, supporting Viatris' strategy to expand access to the treatment in key markets outside of the U.S. and Europe.
Inpefa is the first and only dual SGLT1/2 inhibitor approved for the treatment of heart failure. The treatment is approved in the U.S. and UAE to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.